A Texas-Illinois cancer biotech searches for more Series B capital two years after extension
A Texas biotech trying to treat various cancers, including refractory ones for pediatric patients, is on a winding financing journey.
About 12 months after disclosing a “Series B-3” round in autumn 2019, the Chicago-born biotech attempted raising $50 million, but SEC filings show about $14.5 million of that was secured. Then, starting in late September of this year, Actuate Therapeutics attempted once again to bring in $50 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.